13 results about "Drugs stability" patented technology

The present invention relates to a composition of aliphatic emulsion preparation for malignant thoracicoabdominal hydrops and its preparation method. It is made up by adopting pure natural anticancer medicine elemene and at least one polysaccharide selected from ginseng polysaccharide, astragalus polysaccharide, acanthopanax polysaccharide and lyceum polysaccharide as raw material. Said invention can obviously raise solubility of medicine, increase stability of medicine, effectively remove and kill cancer cells and raise immunity of body.

This application belongs to the field of biomedicine, specifically relating to a method for preparing an antitumor composition for pets, aiming to solve the technical problems of low bioavailability, poor stability, and poor drug administration compliance of poorly soluble active ingredients in antitumor drugs for pets. The method includes: a raw material pretreatment step, in which curcumin, resveratrol, quercetin, green tea polyphenols, and astragalus polysaccharides are pulverized and sieved separately; an organic phase preparation step, in which egg yolk lecithin and solid lipids are dissolved in an ethanol-acetone mixed solvent, and curcumin and resveratrol are added and dissolved by stirring in a water bath; an aqueous phase preparation step, in which poloxamer F68 is dissolved in purified water and dissolved in a water bath; a high-pressure homogenization step, in which a nanoemulsion containing a solid lipid core is prepared; a moderately polar component encapsulation step, in which quercetin and green tea polyphenols are ultrasonically dispersed and then added dropwise to the nanoemulsion; a freeze-drying step, in which a nano-lyophilized powder is obtained; and an outer hydrophilic component coating step, in which astragalus polysaccharides are sprayed or adsorbed onto the surface of the freeze-dried powder. The composition obtained by this method is a core-shell multilayer nanoparticle with a core consisting of curcumin and resveratrol encapsulated by solid lipids, a middle shell adsorbing quercetin and green tea polyphenols, and an outer shell coated with astragalus polysaccharides. This application utilizes the above-mentioned layered encapsulation technology to achieve stable co-encapsulation of multiple antitumor active ingredients, improve the bioavailability of poorly soluble components, optimize drug stability, and enhance antitumor effects through multi-target synergistic effects. Simultaneously, it endows the composition with immunomodulatory functions and sustained-release properties. The composition can be formulated into a nano-lyophilized powder form, making it easy to add to pet food or formulate into a paste for administration, improving pet drug compliance. Figure 2 is a schematic diagram of the three-layer core-shell nanoparticle structure of the composition of this invention.

This invention provides a nasal spray pharmaceutical composition containing CNI 3176, the composition comprising: a therapeutically effective amount of CNI 3176, or a pharmaceutically acceptable salt of CNI 3176, or a mixture of CNI 3176 and a pharmaceutically acceptable salt of CNI 3176. It may also contain pharmaceutically acceptable excipients, such as pharmaceutically used solvents, surfactants, and stabilizers. The composition of this invention contains surfactants and stabilizers, which can improve drug bioavailability and increase drug stability, without requiring control of raw material particle size.

The application provides a curcumin composition-FGF21 functional protein co-assembly microparticle applied to liver diseases and a preparation method thereof, and comprises the following steps: extracting turmeric by dynamic warm soaking, obtaining turmeric filtrate after centrifugation, concentration and microfiltration; preparing high-purity curcumin composition through PS-NVP specific purification and 80% ethanol gradient elution; and preparing Curs-FGF21 co-assembly microparticles through oil-water phase assembly and centrifugation by taking a polymer as a carrier, compounding the curcumin composition with FGF21 protein. The microparticle can improve drug stability and bioavailability, realizes long-acting slow release, can regulate liver cell lipid metabolism, reduce liver lipid accumulation and inflammation, significantly improves liver damage and liver fibrosis, and has outstanding liver protection and repair effects. The process is stable and controllable, has outstanding innovation, and provides a brand-new candidate preparation research and development idea and technical scheme for the prevention and treatment of metabolic liver diseases.

The utility model relates to medicine test technical field, concretely is the temperature control constant humidity box of medicine stability test, including support base, the support base upper surface right -hand side fixed mounting has control mechanism, control mechanism left side installation has test box, the test box includes box, the hinge in box front side surface left end's door, fixed mounting in the middle position of box outside upper surface's motor and rotationally connected in the middle position of box inside's rotating shaft, the rotating shaft outer surface welds have a plurality of test carousel, each the test carousel is placed with a plurality of medicine placing mechanism on every. The utility model discloses through the setting of the rotating disc, makes the medicine in the constant temperature and humidity box when receiving test, can through the rotation and make the test personnel can observe the stability state of all medicines inside, place the medicine in the medicine placing mechanism inside, makes the medicine when the test carousel rotates, the medicine does not roll everywhere, is convenient for the observation of medicine.

A dexamethasone sodium phosphate lyophilized composition suitable for administration to the eardrum and a preparation method therefor are provided. Provided is a lyophilized powder injection preparation, wherein the preparation is a dexamethasone medicament lyophilized powder injection omitting a lyophilization supporting agent or an excipient or a matrix agent, wherein the lyophilized powder injection preparation comprises pharmaceutically acceptable auxiliary material of glycerol, and the glycerol is added before the lyophilized powder injection preparation is lyophilized. The provided lyophilized preparation omits a lyophilized supporting agent or an excipient, achieving the effect of improving the stability of the drug by only adding a small amount of glycerol, and also allowing adjustment the osmotic pressure to be closer to the physiological osmotic pressure during the tympanogram administration and prolong the action time of local administration, thereby increasing the safety and effectiveness of the tympanogram administration.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The application relates to the technical field of pharmaceutical preparations, in particular to a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof; a pharmaceutical composition comprises a co-micronization compound, the co-micronization compound comprises loratadine and a co-micronization carrier; the application discloses a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof, the dissolution rate and stability of the loratadine are improved by adopting the co-micronization technology and a new type of excipient combination; meanwhile, the prepared loratadine immediate-release tablet also has good in-vitro dissolution performance; the loratadine immediate-release tablet prepared by the application reduces impurity growth in the production and storage processes and obviously improves the stability of the drug; the loratadine immediate-release tablet disclosed by the application does not contain lactose in the prescription, so that the side reaction of lactose intolerance can be effectively avoided.

This invention discloses a method for preparing a cyclodextrin-ammonium acetate-naproxen ternary inclusion complex, comprising the following steps: mixing β-cyclodextrin, naproxen, and ammonium acetate in a molar ratio of 0.8-1.3:0.9-1.1:0.8-2.5 with a solvent; stirring the resulting mixture at 35-45°C for 0.5-2 hours; and then removing the solvent by evaporation, standing, and freeze-drying to obtain the ternary complex. This invention prepares a ternary inclusion complex using β-cyclodextrin, naproxen, and ammonium acetate, which significantly improves drug stability and water solubility, thus helping to enhance the bioavailability of naproxen and expand its application areas.

The application discloses a traditional Chinese medicine composition for treating musculoskeletal pain and a preparation method thereof, and belongs to the technical field of medicines. The raw medicine is prepared from the following components in parts by weight: 8-12 parts of rhubarb, 3-6 parts of honeysuckle, 8-10 parts of dandelion, 3-5 parts of red root of madder, 8-10 parts of camptodrome, 6-8 parts of cyperus, 3-5 parts of angelica, 5-7 parts of baizhi, 1-3 parts of mint, 2-5 parts of turmeric and 2-4 parts of notopterygium. The traditional Chinese medicine composition has the advantages of long-lasting efficacy, high safety, comfortable use and strong stability. Compared with traditional cream, the application realizes slow drug release through EC microcapsules, and the analgesic effect of single medication can last for 6-8 hours, so that the medication frequency can be reduced. The amount of hydroxyphenyl ethyl ester is low (0.05%), and the risk of preservative allergy can be reduced. The O / W type substrate has a refreshing texture, good spreadability and no greasy feeling. Nitrogen ketone promotes transdermal absorption of the medicine, and has a fast onset speed. The microcapsule embedding technology improves the stability of the medicine, and the finished product can be stably stored for 18 months under the condition of 40 DEG C and 75% humidity.

This invention discloses a drug stability analysis system, belonging to the field of drug analysis technology. The system includes: a sample data acquisition module, a data fusion and normalization module, an intelligent analysis and state determination module, and a result output and trend prediction module. This invention achieves multi-dimensional and all-round scanning of drug samples during stability testing through the comprehensive application of optical imaging, fluorescence imaging, and infrared imaging technologies. This significantly improves the comprehensiveness and accuracy of data acquisition. Optical imaging technology captures macroscopic surface morphology information of the drug, while fluorescence imaging technology visualizes and tracks specific components in the drug to obtain component distribution information. Infrared imaging technology analyzes the chemical bond vibrations between drug molecules to obtain chemical composition information, providing material for subsequent data analysis and processing.

The application provides a zhisin blood stasis treating composition for treating trigeminal neuralgia, which is formed by scientifically matching six traditional Chinese medicines, such as chuanqiong, jiangcan and shichangpu. Through optimizing the extraction process and the preparation method, the stability and the bioavailability of the medicine are significantly improved. The clinical research shows that the total effective rate of the composition reaches 92.5%, the recurrence rate is as low as 6.5%, and the safety is good, so that a new solution is provided for the treatment of trigeminal neuralgia.